IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that Promedica Prague Group, the largest independent healthcare distributor in the Czech Republic, will bring IndiTreat® products to Czech and Slovakian patients and professionals. This new collaboration agreement brings the total of 2cureX partners to 9, covering 14 European countries and a combined population of 235 million people.
2cureX and Promedica Prague Group have signed an agreement by which Promedica Prague Group becomes the distributor of IndiTreat® products in Czech Republic and Slovakia. Under the terms of the collaboration, Promedica Prague Group will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.
IndiTreat® present in 14 countries
“Promedica Prague Group is the largest independent healthcare distributor in the Czech Republic, also covering Slovakia, and we are thrilled to welcome them as a 2cureX partner. With this agreement, IndiTreat® is distributed in 14 European countries already”, said Fernando Andreu, CEO of 2cureX. “This is outstanding, considering that back in September last year we were present in 6 countries only. The fast expansion reflects the interest our tests are generating in the market”.
“Adding IndiTreat® to our Diagnostics and Pharma product offering will give our sales team yet another very strong and innovative solution for patients and their doctors. As a market leader, it is important that we constantly offer leading edge health solutions” said Hanuś Pavel, CEO Promedica Prague Group.
Czech Republic and Slovakia – two important countries in the center of Europe.
“Czech Republic and Slovakia are two important countries to cover the Central European cancer IVD space, and with the health professionals network of Promedica Prague Group I am very confident that we have found the best partner”, said Jesper Floyd Kristiansen, VP Business Development at 2cureX. “This agreement gives us access to a population of 16 million people, with approximately 12,000 new cases of colorectal cancer every year. We expect IndiTreat® to make a difference for many of these patients going forward“.
The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.